Richard Scott Struthers - 18 Dec 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Tobin Schilke, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
18 Dec 2025
Net transactions value
+$585,890
Form type
4
Filing time
18 Dec 2025, 18:54:46 UTC
Previous filing
30 Sep 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Struthers Richard Scott President & CEO, Director C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO /s/ Tobin Schilke, as attorney-in-fact 18 Dec 2025 0001746298

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $151,654 +16,342 +5.1% $9.28 336,359 18 Dec 2025 Direct
transaction CRNX Common Stock Options Exercise $434,236 +28,400 +8.4% $15.29 364,759 18 Dec 2025 Direct
holding CRNX Common Stock 661,205 18 Dec 2025 By Family Trust 1
holding CRNX Common Stock 106,000 18 Dec 2025 By Family Trust 2
holding CRNX Common Stock 110,000 18 Dec 2025 By Family Trust 3
holding CRNX Common Stock 100,000 18 Dec 2025 By Family Trust 4
holding CRNX Common Stock 1,000 18 Dec 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -16,342 -100% $0.000000 0 18 Dec 2025 Common Stock 16,342 $9.28 Direct F1
transaction CRNX Stock Option (Right to Buy) Options Exercise $0 -28,400 -9.9% $0.000000 259,058 18 Dec 2025 Common Stock 28,400 $15.29 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F2 1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.